Clinica    Scrip    Scrip Regulatory Affairs    Scrip Clinical Research    Animal Pharm   
Email ID
Password
Forgotten password?
Sign me in automatically next time
Home
Market Sector
Business
Policy & Regulation
Regions
News
|
Analysis
|
Features
|
MedTech Ventures
|
People
|
Events
|
Blog
|
Video & Podcasts
|
Science Abstracts
|
clinica
This is a highlight box - testing
14 April 2011

yes.... This is fantastic, now we can have both text and image content on the top of the page and not as Breaking news but as a Highlight!

 
St Jude: CE mark for Genesis migraine therapy the "starting point" of new neurostim opportunity
08 September 2011
St Jude Medical is confident that its Genesis peripheral nerve stimulation (PNS) therapy, which is now CE marked for treating chronic migraine, will play a significant role in driving the company's future growth. This is in spite of uncertainty ...
US FDA improves manufacturer evaluation codes for adverse event device reports
08 September 2011
The US FDA has improved the manufacturer evaluation codes that companies can use when submitting medical device adverse event reports, or MDRs, to the agency. The new codes are expected to help reduce manufacturer reporting burden, improve adverse ...
Sole bidder dispute taints £22m Scottish radiotherapy contract for Varian
28 July 2011
Varian Medical Systems has won a £22m ($36m) contract to supply radiotherapy equipment to five health boards in Scotland through a single procurement contract. The move is significant for the way it was negotiated centrally, rather than on a ...
Medtronic's Resolute DES beats Boston's Taxus in Japanese study
26 July 2011
Medtronic's new-generation drug-eluting stent Resolute has beaten Boston Scientific's Taxus DES, a rival product and one of the established brands in the DES market, in a Japanese clinical study. The positive results should help Medtronic obtain ...
 
St Jude: CE mark for Genesis migraine therapy the "starting point" of new neurostim opportunity
08 September 2011
St Jude Medical is confident that its Genesis peripheral nerve stimulation (PNS) therapy, which is now CE marked for treating chronic migraine, will play a significant role in driving the company's future growth. This is in spite of uncertainty ...
Stryker’s Wingspan clipped by study showing higher stroke risk versus drug therapy
08 September 2011
Stryker’s brain stent system Wingspan has been dealt a blow after a study found that the device, when used to treat clogged arteries in the brain, was linked with an increased risk of stroke and death compared with drug therapy alone. The findings ...
US FDA announces training programmes for device review staff
08 September 2011
The US FDA is introducing two new training programmes to improve the consistency and skill of its medical device unit staff who review pre-market applications. The programmes, designed for reviewers at the FDA’s Center for Devices and Radiological ...
US FDA improves manufacturer evaluation codes for adverse event device reports
08 September 2011
The US FDA has improved the manufacturer evaluation codes that companies can use when submitting medical device adverse event reports, or MDRs, to the agency. The new codes are expected to help reduce manufacturer reporting burden, improve adverse ...
 
Quarterly results round-up: Boston still on road to recovery, Thermo Fisher and Zimmer solid
28 July 2011
Boston Scientific has continued to grow during its second fiscal quarter, helping to allay concerns sparked by CEO Ray Elliott's planned departure. He announced in May that he intends to retire at the end of the year, fuelling fears that the ...
Quarterly results round-up: Alere and Qiagen slash guidance after challenging Q2
28 July 2011
Diagnostics firm Alere has cut its full-year financial guidance to $2.50-2.60 per diluted share, after being hit by lower-than-expected revenues from its health management business. Sales in the unit were down to $135.6m in the second quarter, ...
Quarterly results round-up: St Jude and Quest cut jobs to rein in costs, Baxter strong again
22 July 2011
Devices were a weak spot in Abbott's second fiscal quarter results. Although sales of its Innovation-Driven Devices (comprising its vascular, ophthalmic and molecular diagnostics businesses) increased 3% to $1.2bn, this was due to a 5% favourable ...
NeoStem raises $16.5M as it continues to shift its focus to cell therapy
22 July 2011
NeoStem, the New York-based cell therapy company, plans to raise $16.5m through the sale of 13.8 million share-and-warrant units at $1.20 per unit, a considerable discount to the 18 July stock closing price of $1.32. Each unit comprises a share and ...
 
US FDA announces training programmes for device review staff
08 September 2011
The US FDA is introducing two new training programmes to improve the consistency and skill of its medical device unit staff who review pre-market applications. The programmes, designed for reviewers at the FDA’s Center for Devices and Radiological ...
US FDA improves manufacturer evaluation codes for adverse event device reports
08 September 2011
The US FDA has improved the manufacturer evaluation codes that companies can use when submitting medical device adverse event reports, or MDRs, to the agency. The new codes are expected to help reduce manufacturer reporting burden, improve adverse ...
Brazil courts Iraq’s “valuable unexplored medtech market”
08 September 2011
Iraqi government officials are scheduled to hold a “technical meeting” with Brazilian medtech industry representatives next month in Brasilia to discuss potential supply co-operation agreements. So said the Brazilian industry association, ...
US FDA analysis blames poor quality 510(k) submissions for delays in reviews
28 July 2011
The time it takes for the US Food and Drug Administration to review 510(k) applications for clearing medical devices has increased because of industry's failure to file submissions of an adequate quality, an internal analysis by the FDA has ...
 
PEOPLE
BioCurex strengthens leadership Canadian cancer diagnostics company BioCurex has strengthened its leadership team by appointing Dr Paul Slowey and Mr Trent Davis to its board of ...
It’s official: Gregg Lehman clinches Angeion CEO role Gregg Lehman has been appointed president and CEO of troubled cardiorespiratory diagnostic systems developer Angeion, less than two months after ...
TranS1 makes Ken Reali CEO Orthopaedic firm TranS1 has appointed Ken Reali to the position of CEO. Mr Reali was previously the firm’s president and COO after he joined TranS1 ...
>> More People News...
Successor at Medtronic must choose how to ride out the bumps
23 February 2011
Ashley Yeo

Bill Hawkins’ yet-to-be-appointed successor at Medtronic may be taking over at what is seen as a bad time for the group and the CRM/cardiovascular industry. But the burning question is who will the new chairman and CEO be? The announcement yesterday ...

 
MHIS 2010: All bets are on m-health, but where to start to cash in on opportunities?
08 October 2010
Salina Christmas

Telecommunication providers and mobile phone handset manufacturers need the medtech industry to penetrate the mobile health (m-health) market, it was agreed at the Mobile Healthcare Industry Summit 2010 last week. Medtech is definitely where the ...

 
Out of joint: Japan must nurture markets for innovative technologies
23 June 2011
Derrick Buddles

Japan w ants to develop its medtech industry. So how well does it support the technologies in which it already has a stake? If one was look into the field of joint navigation for an answer, they would find that the response is “Not very well”, ...

Philips to unveil Guardian for wireless hospital monitoring
01 March 2011
Madeleine Armstrong

Philips is to launch its new Guardian software, designed to simplify wireless patient monitoring in hospitals, this year. The firm's marketing director for general care, Andreas Bindszus, spoke to Madeleine Armstrong about the advantages of the ...

Successor at Medtronic must choose how to ride out the bumps
23 February 2011
Ashley Yeo

Bill Hawkins’ yet-to-be-appointed successor at Medtronic may be taking over at what is seen as a bad time for the group and the CRM/cardiovascular industry. But the burning question is who will the new chairman and CEO be? The announcement yesterday ...

 
VIDEOS/PODCASTS
Optos' retinal scanning device
05 January 2010
Get the Flash Player to see this player.
 

Health technology purchasing: will a single selling strategy work?
10 January 2011
Amanda Maxwell

In the EU, policies relating to healthcare financing, as with procurement and reimbursement, are fragmented and their impact is insufficiently understood. Corinna Sorenson*, research officer in European Health Policy at the London School of ...

 
Magnetically-enhanced cell therapy and Philips' cancer biomarkers for personalised treatment
19 July 2011
Phil Greenfield

As of this edition, Clinica’s Patent Watch has changed its focus to medtech areas which are witnessing fast growth. These include regenerative medicine, drug delivery and emerging areas within personalised medicine such as molecular diagnostics. New ...

 
Clinica's MedTech Ventures: Issue 36
28 October 2009

I recently visited Norway with senior business reporter Joseph Harvey to uncover some of the hidden medtech gems there. These were not too hard to find, considering that the country's public healthcare system – which is strongly supportive of ...

 
HUNT Biosciences
12 May 2010
Peter Rixon

Contact Information Halsanvegen 24 7600 Levanger Norway Tel: +47 951 24 048 or +47 951 24 048 Web: www.huntbiosciences.com Email: post@huntbiosciences.com Key Personnel Dr Per A Foss CEO Prof Kristian Hveem Chief scientific officer Håkon Haaheim ...

 
The worldwide clinical diagnostics market – an overview
12 January 2011
InteLab Corporation

The clinical diagnostics market is one of the largest segments of the global medical device and diagnostics industry, ranking third in 2009 after surgical/medical instruments and surgical appliances/supplies. Sales of clinical diagnostics products ...

 
 
 
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Market Sector
Business
Policy & Regulation
Regions
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Clinica
Scrip
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm